Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
"There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis."
Challenging Charcot’s hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.
Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement.
As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.
MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science—and their applications in understanding cause and treatment—the authors offer help to clinicians and hope to patients.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
Da: Lucky's Textbooks, Dallas, TX, U.S.A.
Condizione: New. Codice articolo ABLIING23Mar3113020227779
Quantità: Più di 20 disponibili
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients. 380 pp. Englisch. Codice articolo 9783642437830
Quantità: 2 disponibili
Da: moluna, Greven, Germania
Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The authors offer help to clinicians and hope to patientsAdopts a novel, multifaceted approach to basic scienceControversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with. Codice articolo 5060956
Quantità: Più di 20 disponibili
Da: California Books, Miami, FL, U.S.A.
Condizione: New. Codice articolo I-9783642437830
Quantità: Più di 20 disponibili
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New. Codice articolo 26357312038
Quantità: 4 disponibili
Da: preigu, Osnabrück, Germania
Taschenbuch. Condizione: Neu. Advances in Multiple Sclerosis and Experimental Demyelinating Diseases | Moses Rodriguez | Taschenbuch | xiv | Englisch | 2014 | Springer-Verlag GmbH | EAN 9783642437830 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Codice articolo 104984180
Quantità: 5 disponibili
Da: Majestic Books, Hounslow, Regno Unito
Condizione: New. Print on Demand. Codice articolo 356227577
Quantità: 4 disponibili
Da: Biblios, Frankfurt am main, HESSE, Germania
Condizione: New. PRINT ON DEMAND. Codice articolo 18357312044
Quantità: 4 disponibili
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 380 pp. Englisch. Codice articolo 9783642437830
Quantità: 1 disponibili
Da: AHA-BUCH GmbH, Einbeck, Germania
Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - 'There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis.'Challenging Charcot's hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement. As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science-and their applications in understanding cause and treatment-the authors offer help to clinicians and hope to patients. Codice articolo 9783642437830
Quantità: 1 disponibili